Metabolic syndrome (MetS) forms a cluster of metabolic dysregulations including insulin
resistance, atherogenic dyslipidemia, central obesity, and hypertension. The pathogenesis …

Metabolic syndrome (MetS) includes visceral obesity, hyperglycemia, dyslipidemia, and
hypertension. The prevalence of MetS is 20-25%, which is an important risk factor for chronic …

Objective (s): Metabolic syndrome is a collection of metabolic abnormalities that includes
hyperglycemia, dyslipidemia, hypertension, and obesity. Ellagic acid is found in various …

Statin therapy comprises an integral part of secondary and to a lesser extent of primary
cardiovascular disease prevention. This is attributed not only to their lipid-lowering …

Metabolic syndrome (MetS) is a group of conditions characterized by hypertension (HTN),
hyperglycaemia or insulin resistance (IR), hyperlipidaemia, and abdominal obesity. MetS is …

Background and aim Metabolic dysfunction associated fatty liver disease (MAFLD) is the
most common liver disease and dyslipidemia is commonly considered a prominent risk …

Objective Statin monotherapy for dyslipidemia is limited by adverse effects and limited
effectiveness in certain subgroups like metabolic syndrome. Add-on therapy with an agent …

Hemostasis preserves blood fluidity and prevents its loss after vessel injury. The
maintenance of blood fluidity requires a delicate balance between pro-coagulant and …

The metabolic syndrome (MetS) affects 20–25% of people worldwide and increases the risk
of cardiovascular disease (CVD). MetS is associated with kidney abnormalities, including …

RESUMO A atorvastatina é um fármaco comumente usado para redução da síntese do
colesterol e tratamento da hipercolesterolemia por inibir a 3-hidroxi-3-methyl-glutaril-CoA …